[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

KR940000106A - Stable composition of gastric acid-resistant microgranules of omeprazole and preparation method thereof - Google Patents

Stable composition of gastric acid-resistant microgranules of omeprazole and preparation method thereof Download PDF

Info

Publication number
KR940000106A
KR940000106A KR1019920012770A KR920012770A KR940000106A KR 940000106 A KR940000106 A KR 940000106A KR 1019920012770 A KR1019920012770 A KR 1019920012770A KR 920012770 A KR920012770 A KR 920012770A KR 940000106 A KR940000106 A KR 940000106A
Authority
KR
South Korea
Prior art keywords
omeprazole
active
granules
formulation
diluent
Prior art date
Application number
KR1019920012770A
Other languages
Korean (ko)
Other versions
KR100193966B1 (en
Inventor
르뒤끄 제라르
데브르제아스 빠뜨리스
Original Assignee
데브르제아스 빠뜨리스
에띠파아므 소시에테 아노님
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9430771&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR940000106(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 데브르제아스 빠뜨리스, 에띠파아므 소시에테 아노님 filed Critical 데브르제아스 빠뜨리스
Publication of KR940000106A publication Critical patent/KR940000106A/en
Application granted granted Critical
Publication of KR100193966B1 publication Critical patent/KR100193966B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Sampling And Sample Adjustment (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
  • Epoxy Resins (AREA)

Abstract

The present invention relates to a stable formulation of omeprazole microgranules containing a neutral core consisting of sugar and starch, characterized in that it contains an active layer consisting of a dilution of omeprazole in mannitol in substantially equal amounts. It also relates to a process for producing such formulations.

Description

오메프라졸의 위산-저항성 미소과립의 안정한 조성물 및 이의 제조 방법Stable composition of gastric acid-resistant microgranules of omeprazole and preparation method thereof

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

Claims (10)

활성층이 대략 동일한 양으로 만니를 내 오메프라졸의 회석액으로 구성되는, 당 및 전분으로 구성된 중성핵을 포함하는 오메프라졸 미소 과립의 안정한 배합물.A stable blend of omeprazole micro granules comprising a neutral nucleus consisting of sugar and starch, wherein the active layer consists of a diluent of omeprazole in manny in approximately equal amounts. 제1항에 있어서, 활성 오메프라졸 층은 대략 10% (중량/중량)의 나트륨 전분 글리콜레이트를 함유하는 배합물.The formulation of claim 1, wherein the active omeprazole layer contains approximately 10% (w / w) sodium starch glycolate. 제2항에 있어서, 활성 오메프라졸 층은 나트륨 라우릴 설페이트와 같은 대 략 5%의 표면-활성제를 함유하는 배합물.The formulation of claim 2, wherein the active omeprazole layer contains approximately 5% surface-active agent, such as sodium lauryl sulfate. 제1항 내지 제4항중 어느 한 항에 있어서, 활성 오메프라졸 층의 표면은 만니토를 구성된 부가적인 보호층으로 피복된 배합물.5. The formulation as claimed in claim 1, wherein the surface of the active omeprazole layer is coated with an additional protective layer consisting of mannito. 제1항 내지 제4항 중 어느 한 항에 있어서, 만니톨 내 오메프라졸 희석액 및 상기 보호층은 고점도 히드록시프로필 메틸셀룰로오스와 같은 결합제를 사용하여 직용되는 배합물.The formulation according to any one of claims 1 to 4, wherein the omeprazole diluent in mannitol and the protective layer are employed directly using a binder such as high viscosity hydroxypropyl methylcellulose. 제1항 내지 제5항 중의 어느 한 항에 있어서, 활성 과립은 위산에 대항하는, 히드록실프로필 메틸셀룰로오스프탈레이트 및 활석과 같은 산- 저항성 코우팅으로 구성된 보호 외부충으로 피복되는 배합물.The combination according to any one of claims 1 to 5, wherein the active granules are coated with a protective outer worm consisting of an acid-resistant coating such as hydroxylpropyl methylcellulose phthalate and talc, against gastric acid. 만니틀 내 오메프라졸의 건조 희석액은 에탄올 80%이하 및 물 20%이하의 혼합물의 용액 내의 고점도 히드록시프로핀 메틸셀룰로오스와 같은 결합제를 사용하여 당 및 녹말로 구성된 중성 과립상에 적하되는, 제1항 내지 제6항중 어느 한 항에 따른 배합물을 제조하는 방법.The dry dilution of omeprazole in the mannettle is loaded onto neutral granules composed of sugar and starch using a binder such as high viscosity hydroxypropine methylcellulose in a solution of a mixture of up to 80% ethanol and up to 20% water. A process for preparing a combination according to claim 6. 제7항에 있어서, 건조희석액의 각각의 적용 후에 활성 미소 과립의 물함량을 1%로 감소시키고 이의 에탄올 함량을 2000ppm으로 감소시키기에 충분한 기간 동안 35 내지 47℃의 온도에서 건조시키는 방법.8. The method of claim 7, wherein after each application of the dry diluent, the water content of the active micro-granules is reduced to 1% and dried at a temperature of 35 to 47 ° C. for a period sufficient to reduce its ethanol content to 2000 ppm. 제7항 및 제8항에 있어서, 직경 0.7 내지 0.9㎜ 내의 중성 미소 과립이 사용되는 방법.The method according to claim 7 or 8, wherein neutral fine granules within a diameter of 0.7 to 0.9 mm are used. 제7,8 및 제9항에 있어서, 평평한 바닥 팬은 활성 성분 희석액의 적하 및 위산-저항성 코우팅을 적용하는데 사용되는 방법.10. The method of claim 7, 8 and 9, wherein a flat bottom pan is used to apply dropping of the active ingredient diluent and gastric acid-resistant coating. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019920012770A 1992-06-16 1992-07-16 Stable Composition of Gastric Acid-Resistant Microgranules of Omeprazole KR100193966B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9207249A FR2692146B1 (en) 1992-06-16 1992-06-16 Stable compositions of gastro-protected omeprazole microgranules and process for obtaining them.
FR92-07249 1992-06-16

Publications (2)

Publication Number Publication Date
KR940000106A true KR940000106A (en) 1994-01-03
KR100193966B1 KR100193966B1 (en) 1999-06-15

Family

ID=9430771

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920012770A KR100193966B1 (en) 1992-06-16 1992-07-16 Stable Composition of Gastric Acid-Resistant Microgranules of Omeprazole

Country Status (25)

Country Link
US (1) US5385739A (en)
EP (1) EP0646006B1 (en)
JP (1) JP3568950B2 (en)
KR (1) KR100193966B1 (en)
CN (1) CN1051225C (en)
AT (1) ATE149835T1 (en)
AU (1) AU669719B2 (en)
CA (1) CA2138149C (en)
CZ (1) CZ287260B6 (en)
DE (1) DE69308849T2 (en)
DK (1) DK0646006T3 (en)
ES (1) ES2052458B1 (en)
FI (1) FI111220B (en)
FR (1) FR2692146B1 (en)
GE (1) GEP20002015B (en)
GR (2) GR1001535B (en)
MD (1) MD1472G2 (en)
MX (1) MX9303612A (en)
NZ (1) NZ253179A (en)
PL (1) PL172706B1 (en)
RU (1) RU2103995C1 (en)
SK (1) SK280198B6 (en)
TJ (1) TJ230B (en)
WO (1) WO1993025204A1 (en)
ZA (1) ZA934266B (en)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6426085B1 (en) 1994-05-02 2002-07-30 Josman Laboratories Inc. Use of bismuth-containing compounds in topical oral dosage forms for the treatment of halitosis
US5834002A (en) 1994-05-02 1998-11-10 Josman Laboratories, Inc. Chewing gum containing colloidal bismuth subcitrate
US6902738B2 (en) * 1994-05-02 2005-06-07 Josman Laboratories, Inc. Topical oral dosage forms containing bismuth compounds
ES2087823B1 (en) * 1994-07-13 1997-02-16 Estudes Et Richerches Pharma E FORMULATION OF GASTRORESISTENT MICROGRANULES OF OMEPRAZOLE AND ITS MANUFACTURING PROCEDURE.
JP3743519B2 (en) * 1994-10-18 2006-02-08 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ Method for producing silicon-oxide thin layer
ES2094694B1 (en) 1995-02-01 1997-12-16 Esteve Quimica Sa NEW PHARMACEUTICALLY STABLE FORMULATION OF A COMPOUND OF BENZMIDAZOLE AND ITS PROCESS OF OBTAINING.
US6372784B1 (en) 1995-02-07 2002-04-16 Josman Laboratories, Inc. Bismuth-containing compounds in topical dosage forms for treatment of corneal and dermal wounds
US6379651B1 (en) 1995-02-07 2002-04-30 Josman Laboratories Oral-topical dosage forms for delivering antibacterials/antibiotics to oral cavity to eradicate H. pylori as a concomitant treatment for peptic ulcers and other gastro-intestinal diseases
WO1996024341A1 (en) * 1995-02-07 1996-08-15 Narayan Krishnarao Athanikar Concomitant treatment with bismuth and antibacterials
US5547844A (en) * 1995-02-23 1996-08-20 The Regents Of The University Of California Helicobacter pylori bacterial derived factor
US5945124A (en) * 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
ES2220989T3 (en) * 1995-09-21 2004-12-16 Pharma Pass Ii Llc NEW COMPOSITION CONTAINING LABIL BENZIMIDAZOL TO THE ACID AND PROCEDURE FOR PREPARATION.
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US5840737A (en) * 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
CO4771151A1 (en) * 1996-01-19 1999-04-30 Rachitzky Falicman Pablo Alberto PROCEDURE FOR THE PREPARATION OF A PHARMACEUTICAL PREPARATION CONTAINING NIFEDIPINE AND THE PHARMACEUTICAL PREPARATION OBTAINED THROUGH THE SAME
US6623759B2 (en) * 1996-06-28 2003-09-23 Astrazeneca Ab Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
FR2758459B1 (en) * 1997-01-17 1999-05-07 Pharma Pass FENOFIBRATE PHARMACEUTICAL COMPOSITION HAVING HIGH BIODAVAILABILITY AND PROCESS FOR PREPARING THE SAME
SI9700186B (en) 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Novel pharmaceutical preparation with controlled release of active healing substances
ES2137862B1 (en) * 1997-07-31 2000-09-16 Intexim S A ORAL PHARMACEUTICAL PREPARATION INCLUDING A COMPOUND OF ANTI-ULCER ACTIVITY AND PROCEDURE FOR ITS OBTAINING.
US6174548B1 (en) * 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
FR2771291B1 (en) * 1997-11-21 2000-02-25 Ethypharm Lab Prod Ethiques SPHEROIDS, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS
FR2774288B1 (en) * 1998-01-30 2001-09-07 Ethypharm Sa GASTROPROTEGED OMEPRAZOLE MICROGRANULES, PROCESS FOR OBTAINING AND PHARMACEUTICAL PREPARATIONS
DK173431B1 (en) 1998-03-20 2000-10-23 Gea Farmaceutisk Fabrik As Pharmaceutical formulation comprising a 2 - [[(2-pyridinyl) methyl] sulfinyl] benzimidazole with anti-ulcer activity and progress
ZA9810765B (en) * 1998-05-28 1999-08-06 Ranbaxy Lab Ltd Stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole.
DK1105105T3 (en) * 1998-08-12 2006-07-17 Altana Pharma Ag Oral administration form for pyridin-2-ylmethylsulfinyl-1H-benzimidazoles
US6733778B1 (en) * 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
KR100314351B1 (en) * 1998-10-01 2002-03-21 민경윤 Enteric preparation of benzimidazole derivatives and preparation method thereof
FR2790668B1 (en) * 1999-03-12 2002-07-26 D B F GRANULES CONTAINING A PLANT SUBSTANCE AND THEIR PREPARATION METHOD
FR2793688B1 (en) 1999-05-21 2003-06-13 Ethypharm Lab Prod Ethiques GASTROPROTEGED MICROGRANULES, PROCESS FOR OBTAINING AND PHARMACEUTICAL PREPARATIONS
IL130602A0 (en) 1999-06-22 2000-06-01 Dexcel Ltd Stable benzimidazole formulation
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
US6316020B1 (en) 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
US6262085B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6268385B1 (en) 1999-08-26 2001-07-31 Robert R. Whittle Dry blend pharmaceutical formulations
US6262086B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Pharmaceutical unit dosage form
US6780880B1 (en) * 1999-08-26 2004-08-24 Robert R. Whittle FT-Raman spectroscopic measurement
US6326384B1 (en) 1999-08-26 2001-12-04 Robert R. Whittle Dry blend pharmaceutical unit dosage form
US6312723B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Pharmaceutical unit dosage form
US6312712B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Method of improving bioavailability
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6228400B1 (en) 1999-09-28 2001-05-08 Carlsbad Technology, Inc. Orally administered pharmaceutical formulations of benzimidazole derivatives and the method of preparing the same
GB9923436D0 (en) * 1999-10-04 1999-12-08 American Home Prod Pharmaceutical compositions
DE19959419A1 (en) 1999-12-09 2001-06-21 Ratiopharm Gmbh Stable pharmaceutical preparations comprising a benzimidazole and process for their preparation
ATE297194T1 (en) * 1999-12-16 2005-06-15 Medinfar Produtos Farmaceutico NEW STABLE MULTI-UNIT SUBSTITUTED PHARMACEUTICAL PREPARATIONS CONTAINING BENZIMIDAZOLES
US6346269B1 (en) * 2000-05-08 2002-02-12 Standard Chem. & Pharm. Co., Ltd. Method for preparing an oral formulation containing acid-sensitive drugs and oral formulation made thereby
DE10033023A1 (en) * 2000-07-07 2002-01-31 Biogrund Gmbh Film coating composition based on cellulose derivatives and sugar alcohols
US6749867B2 (en) * 2000-11-29 2004-06-15 Joseph R. Robinson Delivery system for omeprazole and its salts
ES2192929B1 (en) * 2001-04-06 2005-02-16 Laboratorios Belmac, S.A. IMPROVED PROCEDURE FOR OBTAINING STABLE AND GASTRORRESISTENT OMEPRAZOL PELLETS, PELLETS AS WELL OBTAINED AND APPLICATIONS.
US20050163846A1 (en) * 2001-11-21 2005-07-28 Eisai Co., Ltd. Preparation composition containing acid-unstable physiologically active compound, and process for producing same
CA2472103A1 (en) * 2002-01-25 2003-08-07 Santarus, Inc. Transmucosal delivery of proton pump inhibitors
ATE363480T1 (en) * 2002-03-05 2007-06-15 Astrazeneca Ab ALKYLAMMONIUM SALTS OF OMEPRAZOLE AND ESOMEPRAZOLE
PT1524967E (en) * 2002-08-02 2008-04-03 Ratiopharm Gmbh Pharmaceutical preparation containing a benzimidazole compound mixed with microcrystalline cellulose and a method for its preparation
US20040028737A1 (en) * 2002-08-12 2004-02-12 Kopran Research Laboratories Limited Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same
US20050191353A1 (en) * 2002-08-16 2005-09-01 Amit Krishna Antarkar Process for manufacture of stable oral multiple unit pharmaceutical composition containing benzimidazoles
US20040166162A1 (en) * 2003-01-24 2004-08-26 Robert Niecestro Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid
WO2004066982A1 (en) * 2003-01-31 2004-08-12 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and processes for their preparation
WO2004073654A2 (en) * 2003-02-20 2004-09-02 Santarus, Inc. A novel formulation, omeprazole antacid complex-immediate release for rapid and sustained supression of gastric acid
ES2234393B2 (en) * 2003-04-29 2006-09-01 Laboratorios Belmac, S.A. "FORMULATIONS OF PELETS OF ANTIULCEROSE BENCIMIDAZOLIC COMPOUNDS AND LABILS TO THE ACID".
US8993599B2 (en) * 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
MXPA06000529A (en) * 2003-07-18 2006-08-11 Santarus Inc Pharmaceutical composition for inhibiting acid secretion.
CA2531566C (en) * 2003-07-18 2013-05-07 Santarus, Inc. Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders
CN1874764B (en) 2003-10-10 2012-08-01 埃法尔姆公司 Sustained-release microgranules containing ginkgo extract and the process for manufacturing these
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
EP1720527A2 (en) * 2004-03-03 2006-11-15 Teva Pharmaceutical Industries Ltd A stable pharmaceutical composition comprising an acid labile drug
CN1938026A (en) * 2004-03-26 2007-03-28 卫材R&D管理有限公司 Controlled-release pharmaceutical composition and method for producing the same
SI1746980T1 (en) * 2004-05-07 2012-03-30 Nycomed Gmbh Pharmaceutical dosage form comprising pellets as well as its manufacturing process
US8906940B2 (en) * 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) * 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
EP1830823A2 (en) 2004-12-23 2007-09-12 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and process of preparation thereof
AU2006213439A1 (en) * 2005-01-03 2006-08-17 Lupin Limited Pharmaceutical composition of acid labile substances
WO2006087613A2 (en) * 2005-02-02 2006-08-24 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions prepared by non-aqueous layering process
EP1930030A1 (en) * 2005-09-29 2008-06-11 Eisai R&D Management Co., Ltd. Pulse preparation having improved disintegration properties in vivo
EP1785135A1 (en) 2005-11-10 2007-05-16 Laboratorios Del Dr. Esteve, S.A. New stabilized galenic formulations comprising lansoprazole and their preparation
US20070141151A1 (en) * 2005-12-20 2007-06-21 Silver David I Lansoprazole orally disintegrating tablets
AU2007205893A1 (en) * 2006-01-19 2007-07-26 The Curators Of The University Of Missouri Pharmaceutical composition comprising a protein pump inhibitor and protein component
AU2007266574A1 (en) * 2006-06-01 2007-12-06 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
WO2008062320A2 (en) * 2006-10-06 2008-05-29 Eisai R&D Management Co., Ltd Extended release formulations of a proton pump inhibitor
US8911787B2 (en) 2008-02-26 2014-12-16 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and process of preparation thereof
FR2943546A1 (en) * 2009-03-31 2010-10-01 Nouveaux Produits Pharma Sas FUNCTIONALIZED PHARMACEUTICAL EXCIPIENT ENHANCING BIOAVAILABILITY OF LOW SOLUBLE ACTIVE SUBSTANCES, MICROGRANULES INCORPORATING IT.
WO2010122583A2 (en) 2009-04-24 2010-10-28 Rubicon Research Private Limited Oral pharmaceutical compositions of acid labile substances
KR101787481B1 (en) 2010-10-21 2017-10-18 롯데정밀화학 주식회사 Composition for enteric hard capsule and enteric hard capsule prepared by using the composition
PL2773348T3 (en) 2011-11-02 2018-07-31 Laboratorios Del. Dr. Esteve, S.A. Pharmaceutical composition of omeprazole
WO2013122553A1 (en) * 2012-02-14 2013-08-22 Mahmut Bilgic A pharmaceutical formulation comprising an atp-ase inhibitor and method for this formulation
WO2013122554A1 (en) * 2012-02-14 2013-08-22 Mahmut Bilgic Pellet formulations comprising esomeprazole
KR101340733B1 (en) * 2012-12-31 2013-12-12 (주) 에프엔지리서치 Novel microgranule preparations
WO2016174664A1 (en) * 2015-04-29 2016-11-03 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
EP3292862A1 (en) 2016-09-07 2018-03-14 Sandoz Ag Omeprazole formulations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (en) * 1978-04-14 1979-10-15 Haessle Ab Gastric acid secretion
SE457326B (en) * 1986-02-14 1988-12-19 Lejus Medical Ab PROCEDURES FOR PREPARING A QUICK SUBSTANTIAL CANDLES CONTAINING BLA MICROCRISTALLIN CELLULOSA
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
IT1215726B (en) * 1988-01-18 1990-02-22 Alfa Wassermann Spa GALENIC FORMULATIONS WITH SCHEDULED SALE.
US5188836A (en) * 1990-07-27 1993-02-23 Warner-Lambert Company Sustained release formulations
ES2024993A6 (en) * 1990-12-31 1992-03-01 Genesis Para La Investigacion Procedure for obtaining an oral pharmaceutical preparation containing omeprazole

Also Published As

Publication number Publication date
MD960332A (en) 1998-03-31
MD1472G2 (en) 2001-01-31
MX9303612A (en) 1994-04-29
CA2138149A1 (en) 1993-12-23
FI945904A (en) 1994-12-15
CZ287260B6 (en) 2000-10-11
GR3023391T3 (en) 1997-08-29
WO1993025204A1 (en) 1993-12-23
TJ230B (en) 1999-11-24
ATE149835T1 (en) 1997-03-15
SK280198B6 (en) 1999-09-10
DE69308849D1 (en) 1997-04-17
FI111220B (en) 2003-06-30
JP3568950B2 (en) 2004-09-22
EP0646006A1 (en) 1995-04-05
CZ316594A3 (en) 1995-05-17
GR1001535B (en) 1994-03-31
DE69308849T2 (en) 1997-09-04
RU2103995C1 (en) 1998-02-10
ES2052458A1 (en) 1994-07-01
FR2692146B1 (en) 1995-06-02
ES2052458B1 (en) 1995-01-16
NZ253179A (en) 1996-05-28
KR100193966B1 (en) 1999-06-15
ZA934266B (en) 1996-02-09
GEP20002015B (en) 2000-04-10
PL172706B1 (en) 1997-11-28
EP0646006B1 (en) 1997-03-12
CA2138149C (en) 2003-08-19
JPH07508509A (en) 1995-09-21
CN1051225C (en) 2000-04-12
MD1472F2 (en) 2000-05-31
DK0646006T3 (en) 1997-10-13
CN1086130A (en) 1994-05-04
FR2692146A1 (en) 1993-12-17
SK155194A3 (en) 1997-01-08
RU94046268A (en) 1996-10-10
FI945904A0 (en) 1994-12-15
AU4332193A (en) 1994-01-04
US5385739A (en) 1995-01-31
AU669719B2 (en) 1996-06-20

Similar Documents

Publication Publication Date Title
KR940000106A (en) Stable composition of gastric acid-resistant microgranules of omeprazole and preparation method thereof
KR930700615A (en) Aqueous Maltodextrin and Cellulose Polymer Film Coating
US2925365A (en) Coloring solid pharmaceutical forms and compositions therefor
AU627728B2 (en) Film coated tablet
KR940703886A (en) Film Coatings and Film Coating Compositions Based on Cellulosic Polymers and Lactose
FR2514261B1 (en) NOVEL COMPOSITION FOR COATING FOODS AND DRUGS AND GRANULES THUS COATED
IL57728A (en) Hemiesters of steryl glycosides,their preparation and pharmaceutical compositions containing them
FI883404A0 (en) FOERFARANDE FOER ATT ANBRINGA EN FAERGAD BELAEGGNING PAO YTAN AV EN GLASSKIVA. TRANSFERRED PAEIVAEMAEAERAE-FOERSKJUTET DATUM PL 14 ç 21.07.88
AU536920B2 (en) Hydroxypropyl-triazole derivatives and their use as antimycotic agents
BE858797A (en) COATING ENSURING CONTROLLED RELEASE OF ACTIVE INGREDIENTS FROM BIOLOGICALLY ACTIVE PHARMACEUTICAL COMPOSITIONS AND PROCESS FOR PREPARING THESE COMPOSITIONS
KR910011241A (en) Spray drying to prepare pharmaceutical powder compositions that can be compressed directly into tablets
IL49835A (en) Preparation of 2,4-dioxo-1,2,3,4tetrahydro-s-triazino-(1,2-a)benzimidazoles, certain such novel compounds and fungicidal compositions containing them
GB2015488A (en) Stabilised Sodium Aluminosilicate Suspensions
IT8247871A0 (en) DERIVATIVES OF CARBAMATES, INSECTICIDE, ACARICIDE OR NEMATOCIDE COMPOSITIONS WHICH CONTAIN THEM AND PROCEDURE FOR THEIR PRODUCTION AND APPLICATION
IT8024152A0 (en) DERIVATIVES OF 1,1,2-TRIFENYLPROPANE AND 1,1,2-TRIFENYLPROPENE, PROCEDURE FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE COMPOUNDS
IT1117176B (en) DISPERSION OF TETRACHLOROISOPHTHALONITRILE TO BE USED AS AN ANTI-MICROBIAL AGENT FOR PAINTS AND SIMILAR AND PREPARATION PROCEDURE
PT72397B (en) Process for the preparation of n,n-dialkyl-o-(pyrazol-5-yl) carbanic acid derivatives and insecticide and nematicide compositions thereof
IL58367A0 (en) Movel 2-substituted-3-heterocyclylin-dols their preparation and pharmaceutical compositions containing them
JPS54108828A (en) Coating composition of fluorescent substance
DE1169064B (en) Coating agents that form films that can be easily removed again with water
JPS5313641A (en) Fireproof coating compounds
JPS603046B2 (en) improved gelatin capsules
IT7948907A0 (en) DERIVATIVES OF 1,3 BENZODIOXIN PROCEDURE FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS WHICH CONTAIN THEM AS ACTIVE INGREDIENTS
JPH0563131B2 (en)
EP0139767A4 (en) Organophosphorus ester derivatives, process for their preparation, and insecticides containing them as effective ingredients.

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20120201

Year of fee payment: 14

EXPY Expiration of term